NICE final OK extends use of MabThera Pharma Times The National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending Roche's MabThera (rituximab) as an option when used in combination with a wide range of chemotherapy treatments for advanced follicular lymphoma. |
